CASI: Rega Tumbas Perusahaan CASI Pharmaceuticals

CASI Pharmaceuticals (CASI) is implementing environmental standards in the development of leukemia treatments by minimizing the use of chemicals. The company has established an efficient distribution network in China, facilitating access to foreign therapies. This chart illustrates an Enterprise Value of 17.39. However, the business is facing pressure from government procurement, which forcibly reduces drug prices and compresses the issuer's operating profit.

CASI Pharmaceuticals monetizes the adaptation of Western oncology drugs for the Chinese market by leveraging low demand elasticity. Enterprise Value (EV) reflects the total acquisition cost of the business, accounting for net debt. By analyzing changes in business value, an investor sees the sum of market capitalization and liabilities minus cash and cash equivalents. Indicator lows signal either undervaluation or asset degradation. This metric is critical for assessing the real value of licensing rights for molecules.